secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001628280-24-044563
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech Q3 net loss $213.7M; closes Sanofi TCE licensing deal, appoints new CFO
--------------------------------------------------------------------------------

- Net loss $213.7M ($1.56 per share) vs $163.4M ($1.22) in Q3 2023; revenue $2.4M, down from $2.6M.
- Closed exclusive worldwide license with Sanofi for three dual-masked T-cell engagers; paid $103.7M upfront.
- Workforce reduction of ~25% (140 employees) as part of restructuring; expects ~435 employees by year-end.
- Jason O'Byrne appointed as CFO effective Oct 2, 2024; brings 20+ years finance experience.
- R&D expenses surged to $195.2M (including $102.8M Sanofi upfront IPR&D); SG&A down to $25.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024044563/0001628280-24-044563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024044563/vir-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-044563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer